Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies

MT Newswires Live

Apr 08

Telix Pharmaceuticals (ASX:TLX) reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.

Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.

The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.

The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.

Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2625964685"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625964685\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625964685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 06:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625964685","market":"sh","top_or_hot":-1,"title":"Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.</p><p>Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.</p><p>The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.</p><p>The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.</p><p>Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-08 06:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.</p><p>Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.</p><p>The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.</p><p>The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.</p><p>Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX","symbol_name":"Telix Pharmaceuticals Ltd. (Uplisting)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625964685","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625964685","pubTimestamp":1775601847,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TLX":"Telix Pharmaceuticals Ltd. (Uplisting)"},"translate_title":"杰富瑞(Jefferies)表示，Telix Pharmaceuticals美国PSMA PET销售受到关注，市场份额有望增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX":1.5},"content_text":"Telix Pharmaceuticals (ASX:TLX) reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}